Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy: The VANISH Trial.

Coyle K, Coyle D, Nault I, Parkash R, Healey JS, Gray CJ, Gardner MJ, Sterns LD, Essebag V, Hruczkowski T, Blier L, Wells GA, Tang ASL, Stevenson WG, Sapp JL.

JACC Clin Electrophysiol. 2018 May;4(5):660-668. doi: 10.1016/j.jacep.2018.01.007. Epub 2018 Mar 28.

PMID:
29798795
2.

Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).

Parkash R, Nault I, Rivard L, Gula L, Essebag V, Nery P, Tung S, Raymond JM, Sterns L, Doucette S, Wells G, Tang ASL, Stevenson WG, Sapp JL.

Circ Arrhythm Electrophysiol. 2018 Jan;11(1):e005663. doi: 10.1161/CIRCEP.117.005663.

PMID:
29305400
3.

Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.

Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS.

N Engl J Med. 2016 Jul 14;375(2):111-21. doi: 10.1056/NEJMoa1513614. Epub 2016 May 5.

4.

Cost-effectiveness of catheter ablation in patients with ventricular tachycardia.

Calkins H, Bigger JT Jr, Ackerman SJ, Duff SB, Wilber D, Kerr RA, Bar-Din M, Beusterien KM, Strauss MJ.

Circulation. 2000 Jan 25;101(3):280-8.

PMID:
10645924
5.

[Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias].

Ohnishi S, Kasanuki H.

J Cardiol. 2000 Mar;35 Suppl 1:75-84. Review. Japanese.

PMID:
10834174
6.

Prognostic Value of Noninducibility on Outcomes of Ventricular Tachycardia Ablation: A VANISH Substudy.

Essebag V, Joza J, Nery PB, Doucette S, Nault I, Rivard L, Gula L, Deyell M, Raymond JM, Lane C, Sapp JL.

JACC Clin Electrophysiol. 2018 Jul;4(7):911-919. doi: 10.1016/j.jacep.2018.03.013. Epub 2018 May 30.

PMID:
30025692
7.

Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial.

Al-Khatib SM, Daubert JP, Anstrom KJ, Daoud EG, Gonzalez M, Saba S, Jackson KP, Reece T, Gu J, Pokorney SD, Granger CB, Hess PL, Mark DB, Stevenson WG.

J Cardiovasc Electrophysiol. 2015 Feb;26(2):151-7. doi: 10.1111/jce.12567. Epub 2014 Nov 30.

PMID:
25332150
8.

[Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].

Tanner H, Hindricks G, Kottkamp H.

Herz. 2005 Nov;30(7):613-8. Review. German.

PMID:
16333587
9.

Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH.

Gula LJ, Doucette S, Leong-Sit P, Tang ASL, Parkash R, Sarrazin JF, Thibault B, Essebag V, Tung SK, Deyell MW, Raymond JM, Lane C, Nery PB, Veenhuyzen GD, Redfearn DP, Healey JS, Roux JF, Giddens K, Sapp JL.

J Cardiovasc Electrophysiol. 2018 Mar;29(3):421-434. doi: 10.1111/jce.13419. Epub 2018 Jan 30.

PMID:
29316012
10.

Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.

Della Bella P, De Ponti R, Uriarte JA, Tondo C, Klersy C, Carbucicchio C, Storti C, Riva S, Longobardi M.

Eur Heart J. 2002 Mar;23(5):414-24.

PMID:
11846499
11.

Mexiletine or catheter ablation after amiodarone failure in the VANISH trial.

Deyell MW, Steinberg C, Doucette S, Parkash R, Nault I, Gray C, Essebag V, Gardner M, Sterns LD, Healey JS, Hruczkowski T, Rivard L, Leong-Sit P, Nery PB, Sapp JL.

J Cardiovasc Electrophysiol. 2018 Apr;29(4):603-608. doi: 10.1111/jce.13431. Epub 2018 Feb 1.

PMID:
29356207
12.

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.

N Engl J Med. 1997 Nov 27;337(22):1576-83.

13.

Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease.

Inada K, Roberts-Thomson KC, Seiler J, Steven D, Tedrow UB, Koplan BA, Stevenson WG.

Heart Rhythm. 2010 Jun;7(6):740-4. doi: 10.1016/j.hrthm.2010.02.019. Epub 2010 Feb 16.

PMID:
20167290
14.

Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation.

Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ.

Circ Arrhythm Electrophysiol. 2009 Aug;2(4):362-9. doi: 10.1161/CIRCEP.108.837294. Epub 2009 Apr 17.

15.

Prophylactic catheter ablation for the prevention of defibrillator therapy.

Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME.

N Engl J Med. 2007 Dec 27;357(26):2657-65.

16.

Long-Term Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial.

Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld TL, Gonzalez MD, Hsia HH, Schuger CD, Beckman KJ, Bogun FM, Pollak SJ, Bhandari AK.

J Am Coll Cardiol. 2016 Feb 16;67(6):674-683. doi: 10.1016/j.jacc.2015.11.041.

17.
18.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

19.

Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group.

Tzou WS, Tung R, Frankel DS, Di Biase L, Santangeli P, Vaseghi M, Bunch TJ, Weiss JP, Tholakanahalli VN, Lakkireddy D, Vunnam R, Dickfeld T, Mathuria N, Tedrow U, Vergara P, Vakil K, Nakahara S, Burkhardt JD, Stevenson WG, Callans DJ, Della Bella P, Natale A, Shivkumar K, Marchlinski FE, Sauer WH.

Heart Rhythm. 2017 Jul;14(7):991-997. doi: 10.1016/j.hrthm.2017.03.008. Epub 2017 May 12.

PMID:
28506710
20.

Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.

Lynd LD, O'Brien BJ.

J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S99-103. Review.

PMID:
12950529

Supplemental Content

Support Center